

Announcement of Board Resolution to Convene the 2026 Annual General Meeting of Elixiron Immunotherapeutics (Cayman) Limited (KY)

I. Legal Basis:

This notice is issued in accordance with the Company Act, the Securities and Exchange Act, and the resolutions of the Board of Directors passed on March 9, 2026, and April 20, 2026.

II. Announcement Items:

1. Meeting Date: **June 10, 2026.**
2. Book Closure Period: **From April 12, 2026, to June 10, 2026.**
3. Meeting Time: **10:00 AM** (Registration begins at 09:30 AM).
4. Meeting Method: Hybrid (Physical meeting with virtual assistance).
5. Location: 2F, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City.
6. Virtual Meeting Platform: <https://stockservices.tdcc.com.tw> (TDCC Stock Services Platform).

III. Meeting Agenda:

A. Report Items:

1. 2025 Business Report.
2. Audit Committee's Review Report on the 2025 Final Financial Statements.
3. Adoption of the "Code of Ethical Conduct," "Ethical Corporate Management Best Practice Principles," "Procedures for Ethical Corporate Management and Guidelines for Conduct," and "Sustainable Development Best Practice Principles."

B. Ratification Items:

1. Ratification of the 2025 Financial Statements and Business Report.
2. Ratification of the 2025 Deficit Compensation Proposal. *(For details on deficit compensation, please refer to the Material Information and Dividend Distribution section on MOPS: https://mopsov.twse.com.tw/mops/web/t05st09_2).*

C. Discussion Items:

1. Amendment to the "Rules of Procedure for Shareholders' Meetings."
2. Proposal for a cash capital increase via the issuance of new shares for the Initial Public Offering (IPO), where existing shareholders waive their preemptive rights.
3. Amendment to certain articles of the "Articles of Incorporation."

D. Election Items: None. E. Other Proposals: None.

IV. Stock Transfer Procedures:

1. Deadline for Transfer: Before 5:00 PM, April 11, 2026.
2. Transfer Agent: CTBC Bank Co., Ltd., Transfer Agency Department.
 - Address: 5F, No. 83, Sec. 1, Chongqing S. Rd., Taipei City.
 - Phone: +886-2-6636-5566
3. Method: As the last transfer date (April 11, 2026) falls on a holiday, shareholders who hold physical shares but have not registered the transfer must visit the Transfer Agent in person by 4:00 PM on April 10, 2026. For those mailing the application, the postmark date of April 11, 2026, will prevail. For shareholders participating in the TDCC centralized depository, the agent will handle the transfer automatically based on provided data.

V. Shareholder Proposals:

1. According to Article 172-1 of the Company Act, shareholders holding 1% or more of the total issued shares may submit one proposal (limited to 300 words).
2. Acceptance Period: From March 26, 2026, to April 7, 2026.
3. Submission: Must be received by 5:00 PM, April 7, 2026, in writing, marked "Shareholder Meeting Proposal" on the envelope, and sent via registered mail to:
Elixiron Immunotherapeutics Inc. (16F-3, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City).

VI. Other Announcements:

1. Meeting Notice & Proxies: Will be mailed to shareholders 30 days prior to the meeting. If not received, please contact the Transfer Agent.
2. Proxy Solicitation: Solicitors must submit relevant data to Elixiron 38 days before

the meeting and notify the Securities and Futures Institute (SFI).

3. Virtual Meeting Instructions: Participants must register on the TDCC platform between May 11 and June 7, 2026.
4. Contingency Plan: If the virtual platform fails due to force majeure, the meeting will proceed based on the physical attendance quorum as per Article 44-20 of the Regulations Governing the Administration of Shareholder Services.
5. Souvenirs: No souvenirs will be distributed at this meeting.
6. Electronic Voting: * Period: May 11, 2026, to June 7, 2026.
 - Platform: <https://stockservices.tdcc.com.tw>

Official Announcement Link: [MOPS Website](#)